Apollon Formularies PLC (AQSE:APOL), a developer of cannabis-derived drugs targeted at cancer and pain relief, said its focus currently is to access the global export market.
Boosting its production facilities and working with its partners in South Africa will be some of the drivers for this, it added.
“We also hope to be present at more conferences and speaking engagements to further cement Apollon's reputation and increase visibility,” said Stephen Barnhill, chairman and CEO.
Apollon, which aims to be the premier global medical cannabis company in oncology, epilepsy and chronic pain, reported reduced operating losses of £167,000 (£361,000) in the half year to end-June 2022.
First revenues of £165,00 were also booked, while pre-tax losses dropped to £212,000 from £1.7mln.